<DOC>
	<DOCNO>NCT03065998</DOCNO>
	<brief_summary>The aim study examine combination two FDA approve drug , Opipramol baclofen , may increase rehabilitation psychoactive substance . Previous study indicate connection sigma-1 receptor cocaine abuse raise possibility receptor mediator drug craving . However previous study show partial efficacy significant relapse relapse rate . The true use GABAb-1 receptor antagonist . Opipramol selective agonist sigma-1 receptor . It clinically use antidepressant anxiolytic agent . Moreover , previous open control trial indicate GABAb-1 antagonist baclofen partial efficacy suppress withdrawal symptom alcohol addict cocaine . Our study animal model addiction show significant effect combine treatment indicate medication decrease relapse increase -number respondent .</brief_summary>
	<brief_title>Double Blind Placebo Control Opipramol-Baclofen Treatment Addiction</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opipramol</mesh_term>
	<criteria>Age 6018 , sex , seek treatment order stop consumption material Did include trial addict comorbidity , kidney , heart , metabolic , neurological psychiatric disorder ( psychosis , chronic depression ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>